Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combined PD-1 and CTLA-4 Blockade in an International Cohort of Patients with Acral Lentiginous Melanoma.
McGillivray E, Ashouri K, Chatziioannou E, Gallegos JAO, Zarka J, Kechter J, Hwang AS, Zhang K, Barros M, Yeh J, Okazaki I, Crocker AB, Maeda T, Park SJ, Choi J, Andreoli M, Darwish T, Savage DJ, Kim KB, Gupta J, Shen J, Shirai K, Choi A, Pai L, de Lima Vazquez V, Moser J, Amaral T, Hernandez Aya LF, Lutzky J, Najjar YG, Costello CM, Mangold AR, Bhatia S, Gibney GT, Farma JM, Daniels GA, Sosman J, Chandra S, Mangla A, Bollin K, Abrão Possik P, Robles Espinoza CD, Ito F, In GK. McGillivray E, et al. Among authors: chatziioannou e. Br J Dermatol. 2024 Oct 23:ljae401. doi: 10.1093/bjd/ljae401. Online ahead of print. Br J Dermatol. 2024. PMID: 39438074
Nomogram for predicting survival after first-line anti-PD-1-based immunotherapy in unresectable stage IV melanoma: a multicenter international study.
Chatziioannou E, Higuita LMS, Kreft S, Kandolf L, Dujovic B, Reinhardt L, Tamara E, Marquez-Rodas I, Fortuna ARFP, Nübling A, Niessner H, Forschner A, Garbe C, Popovic A, Mirjana B, Meier F, Eigentler T, Leiter U, Flatz L, Sinnberg T, Amaral T. Chatziioannou E, et al. ESMO Open. 2024 Aug;9(8):103661. doi: 10.1016/j.esmoop.2024.103661. Epub 2024 Aug 2. ESMO Open. 2024. PMID: 39096893 Free PMC article.
Isolated melanoma cells in sentinel lymph node in stage IIIA melanoma correlate with a favorable prognosis similar to stage IB.
Amaral T, Nanz L, Stadler R, Berking C, Ulmer A, Forschner A, Meiwes A, Wolfsperger F, Meraz-Torres F, Chatziioannou E, Martus P, Flatz L, Garbe C, Leiter U. Amaral T, et al. Among authors: chatziioannou e. Eur J Cancer. 2024 Apr;201:113912. doi: 10.1016/j.ejca.2024.113912. Epub 2024 Feb 10. Eur J Cancer. 2024. PMID: 38368742 Free article.
PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction In Vitro and In Vivo.
Fröhlich LM, Niessner H, Sauer B, Kämereit S, Chatziioannou E, Riel S, Sinnberg T, Schittek B. Fröhlich LM, et al. Among authors: chatziioannou e. Cancer Res Commun. 2023 Sep 5;3(9):1743-1755. doi: 10.1158/2767-9764.CRC-23-0101. eCollection 2023 Sep. Cancer Res Commun. 2023. PMID: 37674529 Free PMC article.
EGFR expression is associated with relapse in a melanoma cohort receiving adjuvant PD-1-based immunotherapy.
Amaral T, Pop OT, Chatziioannou E, Sinnberg T, Niessner H, Zhao J, Ring SS, Joerger M, Schroeder C, Armeanu-Ebinger S, Cozzio A, Leiter U, Thomas I, Jochum W, Garbe C, Forchhammer S, Levesque M, Mangana J, Hölzel M, Dummer R, Schürch CM, Forschner A, Flatz L. Amaral T, et al. Among authors: chatziioannou e. J Am Acad Dermatol. 2023 Nov;89(5):1072-1074. doi: 10.1016/j.jaad.2023.06.057. Epub 2023 Jul 22. J Am Acad Dermatol. 2023. PMID: 37487833 No abstract available.
Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases.
Chatziioannou E, Roßner J, Aung TN, Rimm DL, Niessner H, Keim U, Serna-Higuita LM, Bonzheim I, Kuhn Cuellar L, Westphal D, Steininger J, Meier F, Pop OT, Forchhammer S, Flatz L, Eigentler T, Garbe C, Röcken M, Amaral T, Sinnberg T. Chatziioannou E, et al. EBioMedicine. 2023 Jul;93:104644. doi: 10.1016/j.ebiom.2023.104644. Epub 2023 Jun 7. EBioMedicine. 2023. PMID: 37295047 Free PMC article.
Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy.
Chatziioannou E, Leiter U, Thomas I, Keim U, Seeber O, Meiwes A, Boessenecker I, Gonzalez SS, Torres FM, Niessner H, Sinnberg T, Forschner A, Flatz L, Amaral T. Chatziioannou E, et al. Am J Clin Dermatol. 2023 May;24(3):453-467. doi: 10.1007/s40257-023-00775-7. Epub 2023 May 4. Am J Clin Dermatol. 2023. PMID: 37142875 Free PMC article.
Identification of stage I/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP).
Amaral T, Sinnberg T, Chatziioannou E, Niessner H, Leiter U, Keim U, Forschner A, Dwarkasing J, Tjien-Fooh F, Wever R, Flatz L, Eggermont A, Forchhammer S. Amaral T, et al. Among authors: chatziioannou e. Eur J Cancer. 2023 Mar;182:155-162. doi: 10.1016/j.ejca.2022.12.021. Epub 2022 Dec 30. Eur J Cancer. 2023. PMID: 36739215 Free article.
13 results